12/05/2022at 15:51

Zealand Pharma rescue pen books USD 0.6m revenue in Q1

On Thursday, Zealand Pharma has publicized its first quarterly report for 2022, stating that rescue pen Zegalogue has generated sales for DKK 4m (USD 0.6m) during the year’s first three months.

by christopher due karlsson, translated by daniel pedersen

Zealand Pharma, a biotech firm publicly listed in Denmark, has released its first quarterly report for 2022 on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Zealand Pharma changes financing agreement
For subscribers
Zealand Pharma's restructuring plan has led to dismissals in Denmark
For subscribers
Newly appointed Zealand Pharma CEO says commercial organization was too expensive
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Per Wold-Olsen officially stepped down as GN's chair at the company's AGM | Foto: Mik Eskestad

Hearing health

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.

For subscribers

Regulation

CHMP recommends nine drugs in March

For subscribers

Nicolai Buhl, executive vice president for innovation at Coloplast, is busy winning a clinical contest against a catheter competitor | Foto: Mik Eskestad

Medtech

Coloplast challenges its biggest catheter competitor in clinical contest

For subscribers

Other

Top news from MedWatch this week

Pharma & biotech

Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit

For subscribers

Pharma & biotech

Novo Nordisk helps Canada resolve Ozempic issue

For subscribers

Novo Nordisk helps Canada resolve Ozempic issue

Americans were reportedly crossing the border seeking the diabetes drug with a strong weight-loss effect until barred from purchases.

For subscribers

Minister for the Interior and Health of Denmark Sophie Løhde must answer questions concerning Novo Nordisk's funding of a Danish patient group | Foto: Ida Marie Odgaard

Pharma & biotech

Danish health minister to answer questions about Novo Nordisk sponsorship of patient group

The Danish minister for health has six business days to answer questions posed by a parliamentarian.

For subscribers

Pharma & biotech

Jefferies raises peak sales estimate for Zealand Pharma obesity drug candidate

The US-based investment bank now thinks the weight-loss drug, co-developed by Boehringer Ingelheim and Zealand Pharma, could generate as much as USD 4.5bn.

For subscribers